
Kynos Therapeutics – a Scottish clinical stage biopharma company focusing on developing novel kynurenine 3-monooxygenase (KMO) inhibitors – has been …

Pfizer is funding a new competitive grants programme to support research projects in the burgeoning, competitive area of cholesterol-lowering PCSK9 …
Ofichem acquires US drug substance CDMO Kinentia
Jager-van Dijk is new Arletta Pharma Solutions CEOÂ
Tridem begins phase Ib trial of Parkinson’s disease vaccine

